Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes may weaken healing power of natural blood membranes

NCT ID NCT07672652

Knowledge-focused Sponsor: Izmir Katip Celebi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study investigates whether type 2 diabetes changes the levels of key growth factors and inflammatory markers in Albumin Platelet-Rich Fibrin (Alb-PRF) membranes—a blood-derived material used to support wound healing and dental tissue repair. Researchers will compare Alb-PRF samples from 10 people with type 2 diabetes and 10 healthy volunteers, measuring interleukin-6, epidermal growth factor, and insulin-like growth factor-1. The goal is to understand if diabetes alters the biological makeup of these membranes, which could affect their effectiveness in regenerative treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Albumin platelet-rich fibrin (Alb-PRF) membranes
What this could lead to
If diabetes alters the composition of Alb-PRF, this could guide personalized regenerative treatments for people with diabetes.
What could go wrong
This is a small, early observational study with only 20 participants. It measures biomarkers, not clinical outcomes, so real-world impact is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Dec 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the type 2 diabetes group: * Diagnosis of type 2 diabetes * HbA1c value of at least 7% * Age over 18 years * Non-smoker * No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months * Not pregnant or lactating * Willingness to participate in the study and signing of the informed consent form For the systemically healthy group: * No history of diabetes or prediabetes * Age over 18 years * Non-smoker * No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months * Not pregnant or lactating * Willingness to participate in the study and signing of the informed consent form Exclusion Criteria: * Age under 18 years * Pregnancy or lactation * Use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months * Smoking * Refusal to participate in the study or not signing the informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Healthy participants

Contacts and locations

Locations

  • İzmir Katip Çelebi University

    Izmir, Cigli, 35620, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.